mFLUSIVA Approval Checks a Box, but Commercial Hurdles Keep Moderna a Wait

What happened

The FDA’s green light for Moderna’s seasonal flu vaccine mFLUSIVA removes the last regulatory uncertainty, with supply expected in select retailers within weeks, but it doesn’t alter our WAIT rating. The market had already priced in this milestone, and the real battle shifts to whether Moderna can convert approvals into durable revenue, especially given that the 65-plus cohort requires a confirmatory study that may limit immediate market share. With $6.91 billion in cash but a $2.1 billion net loss in the first half, a $950 million settlement paid, and up to $1.3 billion in additional legal exposure, the balance sheet remains under pressure. The EU RSV framework still lacks firm purchase orders, and COVID sales are declining, so flu uptake must materialize quickly to stabilize the story. Until we see evidence that flu and RSV are producing more than just regulatory headlines, we stay on the sidelines.

Implication

The approval eliminates a binary risk, but the time to revenue conversion matters: the 2026–27 flu season is short, and procurement decisions are being made now. Without a clean, full approval for the high-value 65-plus segment, mFLUSIVA may face an uphill battle against established enhanced vaccines. Meanwhile, cash eroded from $8.14 billion at year-end to $6.91 billion by June, and the July settlement payment likely brings it closer to $6 billion, leaving little room for setbacks. The EU RSV deal, while promising, hasn’t yet generated orders, and COVID sales are reverting downward. We need Q3 filings to show RSV orders above $100 million and a cash balance above $5.5 billion before turning constructive.

Thesis delta

The approval satisfies the first half of our upgrade condition, but the second—visible RSV order conversion—remains unmet. As the stock had already rallied to $54.8 in anticipation, the risk/reward has not improved meaningfully, and we keep our WAIT rating. The thesis now hinges squarely on commercial execution and cash preservation rather than regulatory catalysts.